Researchers at the University of Alabama at Birmingham have shown — for the first time — that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.
This novel finding, reported in the journal Nature Medicine, is important because, despite significant advances to reveal the pathological mechanisms of persistent fibrosis, effective treatment interventions are lacking.
Pulmonary fibrosis can develop after lung injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in idiopathic pulmonary fibrosis, or IPF. IPF is a progressive, and ultimately fatal, lung disorder that strikes more than 150,000 patients a year in the United States and more than 5 million worldwide.
In experiments using lung tissues from patients with IPF, mouselung fibroblasts and a murine model of lung fibrosis, a team led by Jaroslaw Zmijewski, Ph.D., and Victor Thannickal, M.D., showed the reversal of lung fibrosis and the underlying cellular mechanisms affected by the drug treatment.
Zmijewski and Thannickal are, respectively, associate professor and professor in the UAB Department of Medicine. Zmijewski serves as research director for the Translational Program in ARDS. Thannickal holds the Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease and is director of the UAB Division of Pulmonary, Allergy and Critical Care Medicine.
|Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.|
Interestingly, the drug that accelerated the resolution of lung fibrosis is metformin, which is a safe and widely used agent for non-insulin-dependent diabetes.
The research focused on AMP-activated protein kinase (AMPK), an enzyme that senses energy state in the cell and regulates metabolism. Zmijewski, Thannickal and colleagues found that AMPK activity was lower in myofibroblast cells within fibrotic regions of human lung tissue from IPF patients. Myofibroblasts deposit extracellular collagen fiber as part of the fibrosis process. These myofibroblasts were metabolically active and were resistant to the programmed cell death called apoptosis, a natural process that removes more than 50 billion damaged or aged cells in adults each day.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.
Using a mouse model for lung fibrosis elicited by the anti-cancer drug bleomycin, the research team found metformin treatment, starting three weeks after lung injury and continuing for five weeks, accelerated the resolution of well-established fibrosis. Such resolution was not apparent in AMPK-knockout mice, showing that the effect of metformin was AMPK-dependent.
“Together, our studies support the concept that AMPK may function as a critical metabolic switch in promoting resolution of established fibrosis by shifting the balance from anabolic to catabolic metabolism,” the researchers wrote. “Additionally, we provide proof-of-concept that activation of AMPK by metformin or other pharmacologic agents that activate these pro-resolution pathways may be a useful therapeutic strategy for progressive fibrotic disorders.”
Anabolic metabolism builds up molecules in the cell from smaller units, while catabolic metabolism tears larger molecules into smaller pieces.
Learn more: Metformin reverses established lung fibrosis
The Latest on: Pulmonary fibrosis
via Google News
The Latest on: Pulmonary fibrosis
- Elwyn Berlekamp, game theorist and coding pioneer, dies at 78 on April 18, 2019 at 1:10 pm
from complications of pulmonary fibrosis. A professor emeritus of mathematics and of electrical engineering and computer sciences, Berlekamp was 78. Berlekamp was a “genius” in many areas, according ... […]
- Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965 on April 18, 2019 at 5:00 am
and idiopathic pulmonary fibrosis (IPF), today announced the first healthy volunteer has been dosed in a Phase 1 clinical trial of the company's lead drug candidate IDL-2965. "IDL-2965 reflects true ... […]
- Researchers Use Gene Editing with CRISPR to Treat Lethal Lung Diseases before Birth on April 17, 2019 at 11:24 am
Funding for this work came from the National Institutes of Health (HL134745, HL132999, and TR001878), the UPenn Orphan Disease Center, the Pulmonary Fibrosis Foundation Fund in Cardiovascular ... […]
- CRISPR edits out a deadly lung disease in mice before birth on April 17, 2019 at 11:00 am
Mutations in SFTPC can cause respiratory failure in newborns or idiopathic pulmonary fibrosis later in life. RELATED: CRISPR corrects DMD in mice for a year in Sarepta-supported study Using CRISPR to ... […]
- Blocking TBK1 alleviated radiation-induced pulmonary fibrosis and epithelial-mesenchymal transition through Akt-Erk inactivation on April 15, 2019 at 3:22 am
As a common serious complication of thoracic radiotherapy, radiation-induced pulmonary fibrosis (RIPF) severely limits radiation therapy approaches. Epithelial–mesenchymal transition (EMT) is a direct ... […]
- Long intergenic non-coding RNAs regulate human lung fibroblast function: Implications for idiopathic pulmonary fibrosis on April 15, 2019 at 2:14 am
Phenotypic changes in lung fibroblasts are believed to contribute to the development of Idiopathic Pulmonary Fibrosis (IPF), a progressive and fatal lung disease. Long intergenic non-coding RNAs ... […]
- Your Good Health: Pulmonary fibrosis has no cure; treatment available on April 11, 2019 at 4:29 am
Dear Dr. Roach: My husband was recently diagnosed with mild to moderate pulmonary fibrosis. His mother died from pulmonary fibrosis. From what we have read there is no cure, only palliative care. The ... […]
- Idiopathic pulmonary fibrosis (Influenza) shifted from Kolkata with Global Air Ambulance Services on April 11, 2019 at 12:04 am
(MENAFN - Global Air Ambulance) Thursday, April 11, 2019:- Idiopathic pulmonary fibrosis (influenza) is a dangerous infection or disease caused by a progressive and a deadly symphonic issue in ... […]
- Exact diagnosis is critical to treatment of pulmonary fibrosis on April 10, 2019 at 9:28 pm
DEAR DR. ROACH: My husband was recently diagnosed with mild to moderate pulmonary fibrosis. His mother died from pulmonary fibrosis. From what we have read there is no cure, only palliative care. The ... […]
via Bing News